Rubius Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Rubius Therapeutics

25/02/2022 16:31

* Rubius Therapeutics Inc  RUBY.OQ  reported a quarterly
adjusted
loss of 61 cents​​ per share for the quarter ended in December.
The mean expectation of six analysts for the quarter was for a
loss of 59 cents per share.
    * Reported revenue was zero​;  analysts expected zero. 
    * Rubius Therapeutics Inc's reported EPS for the quarter was
a
loss of 61 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Rubius Therapeutics Inc shares had fallen by 48.2% this
quarter.
    * The company reported a quarterly loss of $55.02 million.
    * Wall Street's median 12-month price target for Rubius
Therapeutics Inc is $17.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 

This summary was machine generated February 25 at 04:31 p.m.
 ​All figures in US dollars unless otherwise stated